SEQUENTIAL METHOTREXATE, 5-FLUOROURACIL (5-FU), AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU AND HIGH-DOSE LEUCOVORIN VERSUS 5-FU ALONE FOR ADVANCED COLORECTAL-CANCER - A MULTIINSTITUTIONAL RANDOMIZED TRIAL

被引:0
作者
ABAD, A
GARCIA, P
GRAVALOS, C
TUSQUETS, I
FONT, A
PEREZ, G
CORTESFUNES, H
FABREGAT, X
BARNADAS, A
ROSELL, R
机构
[1] HOSP GEN GREGORIO MARANON,DEPT MED ONCOL,MADRID,SPAIN
[2] HOSP 12 OCTUBRE,DEPT MED ONCOL,E-28041 MADRID,SPAIN
[3] HOSP DEL MAR,DEPT MED ONCOL,BARCELONA,SPAIN
关键词
FLUOROURACIL; 5-FU; BIOCHEMICAL MODULATION; COLORECTAL CANCER;
D O I
10.1002/1097-0142(19950315)75:6<1238::AID-CNCR2820750605>3.0.CO;2-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. The primary objective of this study was to compare the single-biochemical modulation of 5-fluorouracil (5-FU) and leucovorin with that of the double-biochemical modulation of methotrexate and leucovorin. Because of the Martin et al. study in which an experimental model showed similar effects of 5-FU at maximum tolerated doses to the modulation with leucovorin at standard doses, a third treatment arm of 5-FU alone was also studied. Methods. A randomized trial was performed using a 500-mg/m(2) intravenous (i.v,) 1-hour infusion of methotrexate, and 12 hours later, a 600-mg/m(2) i.v. bolus of 5-FU plus a 200-mg/m(2) i.v. 1-hour infusion of leucovorin (MFL) every 2 weeks versus 5-FU plus leucovorin at an equal dose and schedule (FL), versus a 1200-mg/m(2) i.v dose of 5-FU every 2 weeks. Of 186 patients included in the study, 178 were evaluable. Results. In a preliminary analysis with 94 evaluable patients, two significant statistical differences were shown. First, the toxicity rate of the 5-FU-alone (F) treatment arm was higher than that of the other arms (MFL vs. F, P = 0.0002; FL vs. F, P = 0.00001). Second, the median survival was worse in the F treatment arm with a rate of 12.6 months for the MFL and FL arms and 7.5 months for the F arm (P < 0.05). Considering these results, the F treatment arm was discontinued. The final results included 70 evaluable patients for MFL and 74 patients for FL. No difference was found in the distribution of prognostic factors. The response rates were 25.7% for MFL (95% CI, 16-37.5) and 14.8% for FL (95% CI, 7.6-25), (P = 0.1). The median survival was 14.3 months for patients treated with MFL and 12.3 months for those treated with FL. The hematologic toxicity was mild, with no grade 3/4 leukopenia in either treatment arm. The major nonhematologic toxicity in the MFL and FL treatment arms was ocular; nongrade 3/4 diarrhea also was observed. Conclusions. The results of MFL double-biochemical modulation failed to show a significant statistical difference from that of single-biochemical modulation for this dose and schedule.
引用
收藏
页码:1238 / 1244
页数:7
相关论文
共 50 条
  • [31] A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases
    Naredi, P
    Öman, M
    Blind, PJ
    Lindnér, P
    Gustavsson, B
    Hafström, L
    EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (05): : 459 - 466
  • [32] Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
    Saini, A
    Norman, AR
    Cunningham, D
    Chau, I
    Hill, M
    Tait, D
    Hickish, T
    Iveson, T
    Lofts, F
    Jodrell, D
    Ross, PJ
    Oates, J
    BRITISH JOURNAL OF CANCER, 2003, 88 (12) : 1859 - 1865
  • [33] Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer
    A Saini
    A R Norman
    D Cunningham
    I Chau
    M Hill
    D Tait
    T Hickish
    T Iveson
    F Lofts
    D Jodrell
    P J Ross
    J Oates
    British Journal of Cancer, 2003, 88 : 1859 - 1865
  • [34] Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine
    Chakrabarti, Sakti
    Sara, Jaskanwal
    Lobo, Ronstan
    Eiring, Rachel
    Finnes, Heidi
    Mitchell, Jessica
    Hartgers, Mindy
    Okano, Akiko
    Halfdanarson, Thorvardur
    Grothey, Axel
    CLINICAL COLORECTAL CANCER, 2019, 18 (01) : 52 - 57
  • [35] Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience
    Lima, APR
    Del Giglio, A
    EUROPEAN JOURNAL OF CANCER CARE, 2005, 14 (02) : 151 - 154
  • [36] Effect of Skimmed Milk on the Absorption and Metabolism of 5-Fluorouracil (5-FU) in Animals
    Ahmad, Maqsood
    Ghumman, Shazia Akram
    Alamgeer
    Sharif, Tanveer
    Sher, Muhammad
    Abbas, Tahir
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2012, 11 (01): : 69 - 75
  • [37] Treatment of advanced colorectal adenocarcinoma with weekly high-dose l-leucovorin and 5-fluorouracil
    Nozue, M
    Isaka, N
    Maruyama, T
    Kawamoto, T
    Seino, K
    Tanagichi, H
    Fukao, K
    ONCOLOGY REPORTS, 2002, 9 (01) : 93 - 96
  • [38] A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer
    Kotake, K
    Ohashi, Y
    Kodaira, S
    Koyama, Y
    ONCOLOGY REPORTS, 2005, 14 (01) : 129 - 134
  • [39] A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: A Southwest Oncology Group study
    Robert P. Whitehead
    Jacqueline K. Benedetti
    James L. Abbruzzese
    Bach Ardalan
    Stephen Williamson
    Ellen R. Gaynor
    Stanley P. Balcerzak
    John S. Macdonald
    Investigational New Drugs, 2004, 22 : 467 - 473
  • [40] A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: A Southwest Oncology Group study
    Whitehead, RP
    Benedetti, JK
    Abbruzzese, JL
    Ardalan, B
    Williamson, S
    Gaynor, ER
    Balcerzak, SP
    Macdonald, JS
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (04) : 467 - 473